The BioMed X Institute
30.4.2024 11:31:27 CEST | ACCESS Newswire | Press release
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.
HEIDELBERG, GERMANY / ACCESSWIRE / April 30, 2024 / BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to overcome the immunosuppressive microenvironment of solid tumors.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.Independent of tumor indication, the general immunogenicity of a tumor is positively correlated with a better prognosis and a more robust response to immune checkpoint blockade. The current paradigm envisions tumor mutations as one of the sources of immunogenic neoantigens, which are expressed and presented on the surface of the tumor cells and recognized by the immune system to mount an effective anti-tumor response. The main objective of this research group is to identify how the DNA damage response (DDR) can be harnessed to increase the immunogenicity of tumor cells. The final goal is to design novel therapeutic approaches that promote a favorable tumor microenvironment for immunotherapies.
Dr. Semih Akincilar, the scientist leading this project, explains: "Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment."
The BioMed X Institute and Merck have been collaborating since 2013, partnering on both oncology and immunology research projects, with the end goal of developing new therapies for cancer and autoimmune diseases. "With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology," said Christian Tidona, Founder and Managing Director of the BioMed X Institute. Further details about this project can be found on the BioMed X Institute website (www.bio.mx).
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
SOURCE: BioMed X Institute
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Announces Early Launch of Prime Sale, Featuring Limited Omni Bundle Flash Deals Starting Today18.6.2026 04:00:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / June 17, 2026 / LiberNovo today opened early access to its 2026 Prime Sale, with up to 49% off and a limited run of flash-deal bundles built around the original LiberNovo Omni. Early access is live now, and the full sale runs June 23 through July 11. LiberNovo makes dynamic ergonomic chairs, the first designed to respond to your body as it moves. Instead of locking you into one fixed posture, the dynamic support system keeps the neck support, backrest, armrests, and seat moving together as you shift, lean, and recline. Prime Sale - Omni Series Clearance Deals The original LiberNovo Omni is available at Prime Sale clearance pricing while stocks last, with prices starting as low as €939 (49% off in the EU) and £869 (46% off in the UK), representing significant savings for consumers. The original LiberNovo Omni - the first dynamic ergonomic chair - features an eight-panel Bionic FlexFit Backrest and automatic armrests that move with you through every shif
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders17.6.2026 23:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 17, 2026 / Polaris Renewable Energy Inc. (the "Corporation" or "Polaris") today announced that its annual meeting of shareholders (the "Meeting"), originally scheduled to be held on June 18, 2026 at 9:00 a.m. (Toronto time), has been postponed. The Meeting will now be held as follows: Date: June 26, 2026 Time: 9:00 a.m. (Toronto time) Format: Virtual-only meeting Webcast: https://virtual-meetings.tsxtrust.com/1923 Password: "polaris2026" The Meeting will be conducted in the same virtual format as previously announced, and shareholders will continue to be able to attend, participate and vote online through the TSX Trust virtual meeting platform. Purpose of Postponement The postponement is being done as the required quorum of 50.1% of shareholders voting has not been achieved at this point in time. We encourage shareholders that have not yet voted their shares to do so prior to 9 am on June 25th. Meeting Materials and Business The business of the Meet
Innodata Appoints Jayant Chauhan as Chief Financial Officer17.6.2026 22:30:00 CEST | Press release
Brings More Than Two Decades of Experience in Finance and Scaling High-Growth Technology Companies, Effective July 6, 2026 Interim CFO Marissa Espineli to Transition to Chief Accounting Officer NEW YORK, NY / ACCESS Newswire / June 17, 2026 / INNODATA INC. (Nasdaq:INOD) ("Innodata" or the "Company") today announced that it has appointed Jayant Chauhan as Executive Vice President and Chief Financial Officer (CFO), effective July 6, 2026. At that time, Marissa Espineli, who is serving as the Company's Interim Chief Financial Officer, will transition to the new role of Chief Accounting Officer, reporting to Mr. Chauhan. Mr. Chauhan brings to Innodata more than two decades of experience building and leading finance functions for fast-growing global technology companies. He most recently served as Senior Vice President, M&A at Mphasis, a Blackstone-owned, publicly traded global IT services company, and previously as Senior Vice President, Global Strategic Finance, and CFO of the operated ho
Qualitest Becomes QualityAI: The Trusted Assurance and Engineering Partner Across Every Stage of Enterprise AI17.6.2026 18:45:00 CEST | Press release
As businesses double down on AI deployment, QualityAI helps enterprise leaders move beyond AI claims and go live with confidence. LONDON, UK / ACCESS Newswire / June 17, 2026 / Qualitest, the leading provider of AI-first quality engineering and assurance, today announces its rebrand to QualityAI. The new brand reflects the company's evolution from software testing specialist to AI-first quality engineering partner, helping enterprises design quality into complex systems from the outset. Across every industry, companies are racing to adopt AI, and the pressure to demonstrate progress is rising. According to Deloitte's 2026 "State of AI in the Enterprise" report, the proportion of organizations expecting at least 40% of AI experiments to reach production is expected to more than double within six months. As AI moves from ambition to implementation, leaders need to prove that transformation is real, reliable, and effective. In a market crowded with AI claims, assurance is becoming the dif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom